These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24813654)

  • 1. A transit compartment model unmasks OxyContin's reflective pharmacokinetics from urine measurements in humans.
    Linares OA; Schiesser WE; Linares AD; Stefanovski D; Boston RC
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):96-108. PubMed ID: 24813654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration.
    Cone EJ; Heltsley R; Black DL; Mitchell JM; Lodico CP; Flegel RR
    J Anal Toxicol; 2013 Jun; 37(5):255-64. PubMed ID: 23609023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
    Kirvela M; Lindgren L; Seppala T; Olkkola KT
    J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grapefruit juice enhances the exposure to oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of oral oxycodone in patients after total gastric resection.
    Szałek E; Karbownik A; Murawa D; Połom K; Tezyk A; Gracz J; Grabowski T; Grześkowiak E; Biczysko-Murawa A; Murawa P
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3126-33. PubMed ID: 25392115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients.
    Yee DA; Best BM; Atayee RS; Pesce AJ
    J Anal Toxicol; 2012 May; 36(4):232-8. PubMed ID: 22511697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model.
    Staahl C; Upton R; Foster DJ; Christrup LL; Kristensen K; Hansen SH; Arendt-Nielsen L; Drewes AM
    J Clin Pharmacol; 2008 May; 48(5):619-31. PubMed ID: 18440921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen.
    Couto JE; Webster L; Romney MC; Leider HL; Linden A
    J Opioid Manag; 2009; 5(6):359-64. PubMed ID: 20073409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of oxycodone in patients with cancer-related pain.
    Komatsu T; Kokubun H; Suzuki A; Takayanagi R; Yamada Y; Matoba M; Yago K
    J Pain Palliat Care Pharmacother; 2012 Sep; 26(3):220-5. PubMed ID: 22973910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times.
    Mundin GE; Smith KJ; Mysicka J; Heun G; Krämer M; Hahn U; Leuner C
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1495-503. PubMed ID: 23025349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.
    Cone EJ; DePriest AZ; Heltsley R; Black DL; Mitchell JM; LoDico C; Flegel R
    J Anal Toxicol; 2015 Apr; 39(3):192-202. PubMed ID: 25589778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Charles B; Hardy J; Anderson H; Tapuni A; George R; Norris R
    Support Care Cancer; 2014 Feb; 22(2):325-30. PubMed ID: 24077699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.